Clinical overview on moclobemide

  title={Clinical overview on moclobemide},
  author={John W. G. Tiller},
  journal={Progress in Neuro-Psychopharmacology and Biological Psychiatry},
  • J. Tiller
  • Published 1993
  • Medicine, Psychology
  • Progress in Neuro-Psychopharmacology and Biological Psychiatry
1. Moclobemide is a novel benzamide reversible inhibitor of monoamine oxidase A and has clinical efficacy in a wide spectrum of depressive illness including endogenous and non-endogenous depression, in younger adults and in the elderly. 2. Comparisons have shown similar efficacy to all main classes of antidepressants and much greater tolerability and safety in overdose than tricyclic antidepressants. Clinically, it is neither sedative nor alerting. 3. There is no need for dietary restrictions… Expand
A Risk-Benefit Assessment of Moclobemide in the Treatment of Depressive Disorders
SummaryMoclobemide, a novel benzamide, is a reversible inhibitor of monoamine oxidase-A (RIMA). It has been extensively evaluated in the treatment of a wide spectrum of depressive disorders.Expand
Clinical pharmacology of MAO inhibitors: safety and future.
It seems obvious that a greater understanding of the pharmacodynamics and pharmacokinetics of MAOIs could result in improved treatment of the patients in the future, and selective MAO-B inhibitors and RIMAs hold promise as safer alternatives to classicalMAOIs. Expand
A double‐blind comparison of moclobemide and doxepin in depressed general practice patients
Improvement was negatively correlated with age; this was statistically significant in the total group as well as in the MOC group, with a nonsignificant trend in the same direction in the DOX group. Expand
Moclobemide versus fluoxetine in the treatment of inpatients with major depression.
The data suggest that both agents have a similar efficacy and tolerability but that moclobemide has an earlier onset of antidepressive action. Expand
Antidepressant Toxicity and the Need for Identification and Concentration Monitoring in Overdose
The increasing use of MAO-A inhibitors and SSRIs in the treatment of depression suggests that careful clinical observation is required when combination overdoses are suspected, and qualitative chemical identification of these drugs following overdose is helpful in confirming the diagnosis. Expand
Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19
  • K. Yu, D. Yim, +7 authors S. Shin
  • Chemistry, Medicine
  • Clinical pharmacology and therapeutics
  • 2001
Moclobemide, an antidepressant with selective monoamine oxidase‐A inhibitory action, is known to be metabolized by CYP2C19 and is also reported to be an inhibitor of CYP2C19, CYP2D6, and CYP1A2. ToExpand
The effects of moclobemide on sexual desire and function in healthy volunteers
In both men and women there were no differences between moclobemide and placebo on measures of sexual desire and function, however, men andWomen differed in the levels of reported interest and sexual performance. Expand
Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19.
It is concluded that physicians prescribing moclobemide should pay attention to its pharmacokinetic interactions even on the first day of coadministration with CYP2C19 substrates. Expand
Pharmacologyonline 2 : 68-78 ( 2010 ) Newsletter Shalini
The role of the monoamines, serotonin in mental illnesses including depression is well recognized. All antidepressant drugs in clinical use increase acutely the availability of these monoamines atExpand
The Anxiolytic-Like Properties of Two Selective MAOIs, Moclobemide and Selegiline, in a Standard and an Enhanced Light/Dark Aversion Test
Investigating the putative anxiolytic effects of moclobemide (MOC), a reversible inhibitor of type A monoamine oxidase enzyme (RIMA) antidepressant, in an experimental model of anxiety in mice demonstrated that PTZ-treated mice showed a decrease in the number of transitions as well as in the time spent in the lit area, when compared with vehicle controls, an effect characteristic of an anxiogenic response. Expand


Moclobemide : A Review of its Pharmacological Properties and Therapeutic Use in Depressive Illness.
With its efficacy against endogenous and nonendogenous depression, relatively rapid onset of antidepressant activity, and absence of carry-over effects on treatment withdrawal, moclobemide is likely to make an important contribution to the treatment of major depressive illness. Expand
Efficacy of reversible inhibitors of monoamine oxidase‐A in various forms of depression
The design and the main therapeutic results of 3 controlled double‐blind studies comparing moclobemide with tricyclics and/or placebo in depressed patients are presented and it is shown that reversible inhibitors of MAO‐A demonstrate good efficacy independently of the diagnostic category of depression. Expand
Moclobemide versus clomipramine in endogenous depression. A double-blind randomised clinical trial.
Tolerability was significantly better for moclobemide, as shown by the Clinical Global Impression of Tolerance (CGIT). Expand
Biochemical aspects of the pharmacology of moclobemide. The implications of animal studies.
Administration of moclobemide--a relatively short-acting, reversible inhibitor of monoamine oxidase-A (MAO-A)--to experimental animals potentiates the pressor responses to intravenously injectedExpand
Efficacy and tolerability of moclobemide compared with imipramine in depressive disorder (DSM-III): an Austrian double-blind, multicentre study.
The antidepressant efficacy, tolerability, and safety of moclobemide, a reversible, monoamine oxidase-A inhibitor, were compared with those of imipramine in parallel groups of patients with a majorExpand
The pharmacology of reversible monoamine oxidase inhibitors.
New, reversible monoamine oxidase inhibitors stem from a variety of chemical classes and are more specific in their effects, with relatively rapid onset of action, direct relationship between plasma concentration and pharmacological effect, and no prolonged carry-over phenomena. Expand
Tranylcypromine (Parnate) and phenelzine (Nardil) are frequently prescribed monoamine oxidase (MAO)-inhibiting antidepressants. Although there have been a large number of reports on the effects ofExpand
Moclobemide pharmacokinetics in depressed patients: Lack of age effect
The pharmacokinetics of moclobemide were examined in 19 depressed patients following a single oral dose of 50 mg. Ten patients were aged >60 years and nine <59 years. Plasma concentrations wereExpand
Single-dose pharmacokinetics of the MAO-inhibitor moclobemide in man.
The single-dose kinetics of the MAO-inhibitor p-chloro-N-(2-morpholinoethyl)-benzamide (moclobemide, Ro 11-1163) following oral and i.v. administration to six healthy subjects is described. TheExpand
Tyramine pressor response with moclobemide— A reversible monoamine oxidase inhibitor
Moclobemide is a reversible, short-acting monoamine oxidase inhibitor (MAO1), specific for MAO A. To study moclobemide effects on the tyramine pressor response, we gave 12 depressed patients (2Expand